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Abstract
Background: Mesothelial cells are critical in the pathogenesis of post-surgical intraabdominal adhesions as well as in the
deterioration of the peritoneal membrane associated with long-term peritoneal dialysis. Mesothelial denudation is a
pathophysiolocigally important finding in these processes. Matrix metalloproteinase (MMP) biology underlies aspects of
mesothelial homeostasis as well as wound repair. The endogenous tissue inhibitors of metalloproteinases (TIMPs) moderate
MMP activity.
Methods and Finding: By modifying human TIMP-1 through the addition of a glycosylphosphatidylinositol (GPI) anchor, a
recombinant protein was generated that efficiently focuses TIMP-1 on the cell surface. Treatment of primary mesothelial
cells with TIMP-1-GPI facilitates their mobilization and migration leading to a dramatic increase in the rate of wound
experimental closure. Mesothelial cells treated with TIMP-1-GPI showed a dose dependent increase in cell proliferation,
reduced secretion of MMP-2, MMP-9, TNF-a and urokinase-type plasminogen activator (uPA), but increased tissue
plasminogen activator (t-PA). Treatment resulted in reduced expression and processing of latent TGF-b1.
Conclusions: TIMP-1-GPI stimulated rapid and efficient in vitro wound closure. The agent enhanced mesothelial cell
proliferation and migration and was bioactive in the nanogram range. The application of TIMP-1-GPI may represent a new
approach for limiting or repairing damaged mesothelium.
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Introduction
The peritoneum is a large serous membrane that covers
intraabdominal organs (visceral peritoneum) and lines the
peritoneal cavity (parietal peritoneum). The term peritoneal
membrane is strongly associated with the application of peritoneal
dialysis (PD). The peritoneal membrane consists of an innermost
mesothelial cell monolayer, a basement membrane and the
submesothelial stroma with extracellular matrix components,
connective tissue cellular components and finally vascular and
lymphatic structures. This membrane is used during PD as a
semipermeable membrane that allows movement of urophanic
substances and water in the abdominal cavity permiting the
adjustment of electrolytes and acidbase homeostasis. Mesothelial
injury by toxic, inflammatory (PD), mechanic or ischaemic
(surgery) stimuli can lead to disturbance in the homeostatsis of
the membrane. The identification of agents that could prevent or
promote membrane repair is an important issue in mesothelial
biology.
The MMPs are a large family of structurally related enzymes
that collectively degrade extracellular matrix (ECM) [1]. The
balance between MMPs and their endogenous inhibitors, the
TIMPs, help to regulate ECM turnover during normal tissue
homeostasis and pathogenesis. These proteins can also play key
roles in moderating cell signaling through the cleavage of
precursor proteins or proteolytic modification of cyokines or
growth factors [2].
MMP/TIMP biology is important to peritoneal mesothelial cell
homeostasis and repair [3]. Mesothelial cells can directly
participate in the extracellular matrix turnover that follows serosal
injury via elaboration of MMPs and TIMPs. The state of cellular
differentiation appears to have an important influence on MMPs/
TIMP expression such that epitheloid cells often display a more
PLoS ONE | www.plosone.org 1 April 2012 | Volume 7 | Issue 4 | e33963matrix-degradative phenotype (increased MMP and decreased
TIMP) than their fibroblastoid counterparts [4].
GPI-anchored proteins are efficiently transferred from one cell
to another through a process called cell painting or cell surface
engineering [5,6]. Modification of human TIMP-1 protein by the
addition of a GPI anchor results in an agent that with enhance
bioactivities which depend upon the cell system under study
[6,7,8]. Recombinant TIMP-1-GPI fusion protein was shown to
be readily incorporated into mesothelial cell surface membranes
thus focusing the biologic actions of TIMP-1 directly onto the cell
surface. We then evaluated the response of mesothelial cells to
treatment with recombinant TIMP-1-GPI using a mechanical
wound model and related in vitro assays. Our results demonstrate a
strikingly accelerated wound closure rate following treatment of
mesothelial cells with TIMP-1-GPI, as well as modulation of the
fibrogenic milieu. These effects were linked in part to reduced
TNF-a and TGF-b1 production by the mesothelial cells.
Materials and Methods
Medium M199 and newborn calf serum were obtained from
Gibco BRL (Eggenstein, Germany), tissue culture plates were from
Costar (Cambridge, MA, USA). Human serum was prepared from
freshly collected blood of healthy donors and stored at –20uC.
Fibronectin from human serum and trypsin were purchased from
Boehringer (Ingelheim, Germany).
Cell Culture Experiments
Primary human mesothelial cells were isolated from the omental
tissue of consenting patients undergoing elective surgery as
described in [9]. The studies were reviewed and approved by
the University Ethics Committee. Cells were grown in fibronectin-
coated dishes in M199 medium supplemented with 25 mM Hepes
(pH 7.3), 2 mM glutamine, 10% (vol/vol) human serum, 10%
(vol/vol) newborn calf serum (heat-inactivated), penicillin (100 U/
ml) and streptomycin (100 mg/ml) at 37uC under 5% CO2/95%
air atmosphere. The medium was replaced every two to three
days. Subcultures were obtained by trypsin/ethylenediaminetet-
raacetic acid (EDTA) treatment at a split ratio of 1:3. Cells from
omental tissue were human mesothelial cells as assessed by their
uniform cobblestone appearance at confluence, by the absence of
von Willebrand factor and the uniform positive staining for
cytokeratins 8 and 18 and for vimentin. For the in vitro
experiments, confluent cultures were used at the second or third
passage, and cells were always given fresh media 48 hours before
the experiment (M199 medium, supplemented with 2% (vol/vol)
human serum and antibiotics). Confluent cells were demonstrated
to be in a non-proliferative state under these conditions [10].
Fluorescence-activated Cell Sorting (FACS) Analysis
Cells were detached with 1.5 mM EDTA (Biochrom A, Berlin,
Germany No. L2113) in 16PBS and incubated for 60 min on ice
with antibodies specific for human; TIMP-1 (IM32L), MMP-3
(IM36), MMP-2 (MS-806 PiABX) (Thermo Scientific Dreieich,
Germany), MMP-9 a gift from Dr. Christian Ries (Chirurgische
Klinik and Poliklinik, LMU), ICAM-1 (ICAM-I9GP89-11) a gift
from Judith Johnson (Institute of Immunology, LMU) and
VCAM-I (DAKO A/S, Glostrup, Denmark No. M7106) were
described previously [6]. Cells were washed three times with
16PBS, incubated with FTIC-conjugated anti-mouse mAB
(DAKO A/S, Glostrup, Denmark No. F0313) for 45 min on ice,
then washed three times with 1 x PBS and analyzed using a flow
cytometer (FACSCalibur, Becton, Dickinson and Company, San
Jose, CA, USA) and CellQuest software.
Purification of TIMP-1-GPI Protein
The TIMP-1-GPI protein was produced and purified as
previously described [6]. Briefly, human TIMP-1 was cloned
from cDNA using hTIMP-1 specific primers, fused without a
translation stop codon to the GPI-signal sequence cloned from
LFA-3 [11,12], subcloned into pEF-DHFR and stably introduced
into DHFR deficient Chinese hamster ovary [13] cells and selected
as described [14]. TIMP-1-GPI-fusion protein was subsequently
purified from the CHO cells by Triton X-100 detergent extraction
followed by column purification using DEAE, heparin sepharose
and size exclusion as described [6].
ELISAs and uPA Activity Assay
A human TIMP-1 specific ELISA kit was used to monitor levels
of purified TIMP-1 in solution (BMS2018MST, Bender MedSys-
Figure 1. TIMP-1-GPI reincorporation into mesothel cells. To
demonstrate the efficiency of reincorporation of GPI-anchored TIMP-1
protein into cell membranes, purified TIMP-1-GPI (14 ng/ml) or control
rhTIMP-1 (14 ng/ml) was added to primary human mesothelial cells and
TIMP-1 was then detected on the cell surface using an anti-human
TIMP-1 monoclonal antibody and FACS analysis. The grey histograms
represent isotype control stainings while the solid-line histograms
represent TIMP-1 antibody signal.
doi:10.1371/journal.pone.0033963.g001
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performed on cell culture supernatants using commercial assay kits
(QuantikinH, R&D Systems, Minneapolis, USA, No. 691228 and
762138) and t-PA ELISA from (TC Technoloclon, Wienna,
Austria, No. TC12007). ELISA for PAI-1 was preformed on cell
lysates using commercial assay kit (R&D Systems, Minneapolis,
USA, No. DSE100).
UPA activity assay was performed on cell culture supernatants
using commercial assay kits (SPECTROZYMEH uPA, American
Diagnostica GmbH, Pfungstadt Germany, No. 224L). Enzyme
activity is determined by measuring the increase in absorbance of
the free chromophore (pNA) generated per unit time at 405 nm.
At excess substrate concentrations, the rate at which the
absorbance increases due to the amount of chromophore released
is linearly related to enzyme concentration. The Extinction
Coefficient for SPECTROZYME uPA is 9650 M
21cm
21 and
the concentrations were calculated through Beer-Lambert-Law.
TGF-b1 ELISA. Latent and active forms of TGF-b1 was
measured using a commercial ELISA kit (DB Biosciences, San
Jose, CA USA, No. 559119) used according the manufacture’s
directions.
Incorporation of TIMP-1-GPI into Cell Membranes
Primary human mesothelial cells (5210610
6 cells/ml) were
incubated with 14 ng/ml of purified hTIMP-1-GPI at 37uC/5%
CO2 for 60 min. The cells were then washed one time with serum
free medium and analyzed by FACS using human TIMP-1
specific monoclonal antibodies (see above).
Proliferation
Primary human mesothelial cells (30610
3/100 ml medium)
were cultured in 96-well micro-titer plates for 24 h under standard
conditions to yield firmly attached and stably growing cells. After
discarding supernatants, 50 ml of medium containing TIMP-1-
GPI, buffer, or rhTIMP-1 was added to cells and incubated for 24
to 72 h. Then 50 ml of a 1 mg/ml solution of (3,5-Dimethylthia-
zol-2-yl] – 2,5 – diphenyl-tetrazolium bromide) MTT (SIGMA-
ALDRICH, Taufkirchen, Germany No. M2128) was added. After
3-h incubation at 37uC, formazan crystals were dissolved by
addition 100 ml isopropanol and 0.04 N HCl. Absorbance was
then measured at 590 nm using GENios plus TECAN ELISA
reader. For each experiment at least 6 wells were analyzed per
experimental condition and time point.
Zymography. Primary human mesothelial cells were
cultured in 24 wells plate (5610
4 cells/well). The medium was
exchanged for 24 h with serum-free medium containing either
rhTIMP-1, or other controls and increasing amounts of TIMP-1-
GPI and incubated for 24 h, 48 h and 72 h. Cell supernatants
were analyzed by gelatin zymography using 10% SDS-
polyacrylamide gels (Invitrogen, Groningen, Netherlands, No.
EC61755BOX) as described [6]. Recombinant MMP-9 enzyme
(Amersham Biosciences, Uppsala, Sweden, No. RPN2634) was
used as positive control.
Wound healing assay. Uniform wounds were introduced
into the cell culture system by using the ibidi Culture-Insert (ibidi
GmbH Munich, Germany, No. 80209). This approach provides
two cell culture reservoirs with a separation wall of 500 mm thick.
The culture-Inserts were placed in the individual wells of a six well
plate. In each reservoir, 3000 mesothelial cells were cultured with
an end volume of 100 ml. The silicon inserts were removed after
the cells had undergone adherence. The gaps created (or wounds)
were washed with serum-free medium and each well was filled
with 2 ml sample (medium, vehicle, 14 ng/ml rhTIMP-1 or
TIMP-1-GPI).
Wound closure was then monitored by tracing the wound area
using recording. Images were acquired every 10 min using a Meta
Morph controlled Nikon camera (Fluorescence Inverted micro-
scope (Nikon 2000 E, Nikon GmbH Duesseldorf, Germany) at
37uCb yC O 2 supply for 24 h. The microscope system was pre-
heated for several hours before starting the experiment. The
microscope function was controlled by NIS elements software.
Pictures were taken every 7 min for 24 h. Movie was edited with
QuickTime Pro and iMovie software from Apple Inc. The closing
areas were calculated using imaging software NIS-Elements
(Nikon GmbH Duesseldorf, Germany). The software was used
to determine changes in the wound surface over time. The data
was automatically incorporated into Excel program for further
analysis.
Results
Cell Surface Engineering of Primary Human Mesothelial
Cells by the Addition of Recombinant TIMP-1-GPI
GPI-anchored TIMP-1 protein was generated and isolated as
previously described [6,7,8]. The efficiency of incorporation of
recombinant GPI-anchored TIMP-1 protein into the surface
membranes of primary human mesothelial cells was determined
after incubation of the cells with 14 ng/ml of purified TIMP-1-
GPI, recombinant human (rh)TIMP-1 control protein or vehicle
for one hr at 37uC. Surface associated TIMP-1 protein was
detected using fluorescence-activated cell sorting (FACS) using an
anti-human TIMP-1 monoclonal antibody (Figure 1). Addition of
vehicle or control rhTIMP-1 protein did not lead to a change in
the FACS shift. Treatment with GPI-anchored TIMP-1 resulted
in a strong surface signal for human TIMP-1 protein.
Cell Surface Associated TIMP-1-GPI Protein Lead to a
Block in the Release of proMMP-2 and proMMP-9 from
Mesothelial Cells
Human primary mesothelial cells constitutively secrete both
proMMP-2 and proMMP-9 proteins as seen by gelatinase
zymography (Figure 2). These proteins have been previously
linked to mesothelial biology [15]. The effect of increasing surface
TIMP-1 protein levels on the secretion of MMP-2 and MMP-9
proteins was evaluated [6,16]. While treatment with vehicle or
rhTIMP-1 protein (14 ng/ml) had no effect on MMP-2 or MMP-9
secretion, by contrast, starting at 8 ng/ml, addition of TIMP-1-
Figure 2. TIMP-1-GPI inhibits release of pro-MMP-2 and pro-
MMP-9 from mesothel cells. TIMP-1-GPI inhibits the secretion of
pro-MMP-2 and pro-MMP-9 from mesothelial cells. Gelatinase zymo-
graphy was used to characterize the level of MMP-2 and MMP-9
proteins in mesothelial cell culture supernatants. The cells were treated
with increasing amounts of TIMP-1-GPI (0214 ng/ml), or control
rhTIMP-1 (14 ng/ml), and after 48 h the serum-free culture supernatant
was removed and analyzed on a gelatinase zymography gel [16].
doi:10.1371/journal.pone.0033963.g002
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both MMP-2 and MMP-9 into the growth media.
Cell Surface Engineering with TIMP-1-GPI is Associated
with an Increase in Cell Surface Associated MMPs
TIMP-1 is known to bind most active forms of MMPs. Based on
the results of the gelatinase experiments, it was suggested that
TIMP-1-GPI could potentially sequester the normally secreted
MMPs on the surface of the TIMP-1-GPI ‘‘engineered’’ cells.
Following incubation of mesothelial cells with 14 ng/ml of TIMP-
1-GPI protein for 24 h, FACS analyses using MMP-1, MMP-2,
MMP-3 and MMP-9, showed an increase in mean channel
fluorescence intensity (MFI) for MMP-1, MMP-2, MMP-3, and
MMP-9 on the TIMP-1-GPI treated cells, but not on the rhTIMP-
1 control cells. ICAM-1 and VCAM-1 expression is associated
with leukocyte recruitment to damaged mesothelium. Specific
antibodies directed against these proteins were used to evaluate the
effect of treatment on their expression. While ICAM-1 remained
unchanged, a moderate increase in VCAM-1 was seen (Figure 3).
Treatment of Primary Human Mesothelial Cells with GPI-
anchored TIMP-1 Lead to a dose Dependent Increase in
their Proliferation
We have previously shown that treatment with TIMP-1-GPI
can either enhance or suppress cell proliferation depending on the
specific cell type studied [6,7,8]. To assess the effect of TIMP-1
surface engineering on the proliferation of primary mesothelial
cells in vitro, MTT assays were performed. The exogenously added
TIMP-1-GPI protein was found to elicit a dose-dependent
increase in the proliferation of primary human mesothelial cells
(Figure 4).
Treatment with TIMP-1-GPI Stimulates Rapid Mesothelial
wound Closure in an In Vitro Model of Mesothelial wound
Healing
To helpcharacterizethe effectofTIMP-1 surfaceengineering on
directionalcell migrationasassociated withwoundrepair,an invitro
wound-healing model was applied and the effect of TIMP-1-GPI
treatmentevaluated.Theapproachinvolvescreatinga‘‘wound’’ona
monolayer of primary human mesothelial cells using a commercial
apparatus(ibidi,Munich,Germany),treatmentofthecellswitheither
recombinant TIMP-1-GPI protein or control protein, and then
capturingvideoimagesfromtheinitiationoftheexperimentthrough
to wound closure. The combined migration rate and proliferation
effectwasthenquantifiedusingimagingsoftware(NIS-Elements,see
Materials and Methods).
While treatment of the ‘‘wounded’’ primary mesothelial cell
monolayerwithgrowthmedium,vehicleorrhTIMP-1proteinalone
lead to only limited wound closure by 24 h, application of TIMP-1-
GPI at7 ng/ml or14 ng/ml lead to a rapidwound closure by20 or
16 h respectively (Figure 5) (Video S1, S2, S3, S4, S5).
TIMP-1-GPI Treatment Lead to a Reduction in uPA, PAI-1
and TNF-a Secretion/Activity Levels, but Increased t-PA
by Human Mesothelial Cells
Tissue plasminogen activator (t-PA) and the urokinase plasmin-
ogen activator (uPA) are fibrinolytic agents while plasminogen
activator inhibitor-1 (PAI-1) inhibits their activity. Alterations in
these proteins have been linked to PD and general mesothelial
damage [17,18,19,20]. While mesothelial cell surface engineering
with TIMP-1-GPI lead to a dose dependent increase in t-PA
secretion, a decrease in uPA and PAI-1 secretion was seen by 12 h
(Figure 6 A-C). The observation that tPA is enhanced, while uPA
and PAI1 are reduced can be explained in part by the effect of
TIMP-1-GPI treatment on the steady state mRNA expression of
these genes (Text S1). While TIMP-1-GPI lead to an increase in
steady state mRNA levels of t-PA, a reduction in PAI-1 mRNA
was seen (Figure S1).
TNF-a is a general activator of inflammatory processes and can
also promote apoptosis of mesothelial cells [21]. [22]. Treatment
of the human mesothelial cells with TIMP-1-GPI lead to a dose
dependent reduction in TNF-a release and reduced steady state
mRNA expression (Figure 6 D, Text S1 and Figure S1).
Treatment Leads to Reduction in the Processing and
Secretion of TGF-b1.
Mesothelial proliferation and migration can be inhibited by
TGF-b1 [23]. TGF-b1 is also strongly associated with wound
healing in general [24,25]. ELISA was used to assess the secretion
of total vs. active forms of TGF-b1 by primary mesothelial cells
with and without treatment with TIMP-1-GPI or control protein.
While total TGF-b1 was moderately reduced by treatment with
TIMP-1-GPI (Figure 7), treatment led to reduction in active
TGF-b1 suggesting an effect on proteolytic processing of the latent
TGF-b1 complex (Figure 7).
Figure 3. Effect of rhTIMP-1 and TIMP-1-GPI protein on the surface expression. Following incubation of mesothelial cells with 14 ng/ml of
TIMP-1-GPI protein for 24 h, FACS analyses was performed using MMP-1, MMP-2, MMP-3, MMP-9, ICAM-1 and VCAM specific antibodies. The results
show that treatment with TIMP-1-GPI, but not rhTIMP-1 lead to an increase in mean channel fluorescence intensity (MFI) for MMP-1, MMP-2, MMP-3
and MMP-9. VCAM and ICAM-1 are associated with the inflammatory status of the cells (they are involved in leukocyte recruitment). While VCAM was
moderately increased, ICAM-1 levels remained unchanged with treatment.
doi:10.1371/journal.pone.0033963.g003
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Figure 4. Effect of rhTIMP-1 and TIMP-1-GPI protein on the
proliferation of human mesothel cells. The effect of increasing
levels of TIMP-1-GPI or rhTIMP-1 control protein on the proliferation of
primary human mesothelial cells was measured using an MTT assay [49].
MTT was added after 24, 48 or 72 h as indicated. TIMP-1-GPI treatment
was found to enhance proliferation of the mesothelial cells while no
effect was seen with rhTIMP-1 or dTIMP-GPI.
doi:10.1371/journal.pone.0033963.g004
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Wound healing involves the orchestration of a series of cellular
and biochemical events many of which are linked to aspects of
MMP/TIMP biology [26,27,28]. We evaluated the effect of a
novel TIMP based reagent on processes associated with mesothe-
lial repair. Recombinant TIMP-1-GPI was shown to be efficiently
incorporated into cell membranes leading to a shift in the
association of TIMP functional domains from the pericellular
environment to the cell surface (Figure 8). This treatment led to
moderation in the expression of cytokines and growth factors by
mesothelial cells. TIMP-1-GPI also reduced MMP-2, MMP-9,
TGF-b1 and TNF-a secretion, and altered the balance between
uPA, t-PA and PAI-1 expression. The reduced gelatinase
production seen may result in part from the sequestering and
blockade of MMPs directly on the surface of treated cells.
Treatment also led to enhanced mesothelial cell proliferation and
Figure 5. TIMP-1-GPI promotes wound healing in vitro. A monolayer of human primary mesothelial cells was cultured with an experimental
wound model insert provided by Ibidi GmbH (Munich, Germany). Removal of the insert yielded a uniform ‘‘wound’’ to the monolayer. (A) Treatment
with TIMP-1-GPI but not the control proteins, showed a dose dependent increase in wound closure. (B) The closing areas were calculated using
imaging software NIS-Elements. (Video S1, S2, S3, S4, S5).
doi:10.1371/journal.pone.0033963.g005
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healing assay (Figure 7 and 8).
Mesothelial cells represent the largest population of resident
cells in the peritoneal cavity. They provide a non-adhesive and
protective layer against foreign particles and injury to the
peritoneum [29]. Mesothelial cells play a central role in the
process and function of peritoneal dialysis. Any morphologic
changes of the mesothelium are likely to have an impact on PD
[30,31]. During normal mesothelial repair, cells in the peritoneal
fluid implant in depopulated peritoneal areas. Mesothelial cells can
also migrate from the connective tissue to the peritoneal surface
and replicating cells from the borders of denuded zones become
mobilized and migrate to facilitate repair [32]. Thus, mobilization
and proliferation of these cells is central to efficient wound healing.
MMPs play diverse roles in wound healing [33]. They degrade
the ECM. A balance between this activity and ECM production
underlies optimal wound healing. MMP biology is also associated
with the regulation of cell cycle and cellular proliferation [34,35].
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Figure 6. The effect of TIMP-1-GPI on t-PA, PAI-1, TNF-a and uPA protein secretion on human mesothelial cells. A quantitative
assessment of protein expression was analyzed using specific ELISA and activity assays after 12 h TIMP-1-GPI treatment. (A) t-PA release was
increased in dose dependent manner of TIMP-1-GPI whereas the secretion of PAI-1 (B) decreased under the same conditions. (C) The release of uPA
was decreased in human mesothelial cells when the cells after 12 h treatment with TIMP-1-GPI. (D) TNF-a protein was also reduced by treatment with
TIMP-1-GPI. Denatured dTIMP-GPI had no effect.
doi:10.1371/journal.pone.0033963.g006
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Figure 7. TIMP-1-GPI treatment reduces activation of TGF-b1.
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doi:10.1371/journal.pone.0033963.g007
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(TIMP-1, TIMP-2, TIMP-3 and TIMP-4), which are produced by
most cells, and inhibit MMPs in a 1:1 ratio.
TIMPs can have diverse biologic effects that depend on the
context of their expression [36]. We have previously shown that
engineering TIMP-1 by the addition of a GPI anchor results in a
recombinant protein that has enhanced and novel bioactivities
depending on the cell type studied and activation status [6,7,8].
TIMP-1-GPI treatment of mesothelial cells in the context of a
mechanical in vivo wound healing model demonstrated early and
efficient wound closure. This effect was associated with enhanced
proliferation, mobilization and migration of the cells.
Mesothelial cells express adhesion molecules, including inter-
cellular adhesion molecule-1 (ICAM-1) and vascular cell adhesion
molecule-1 (VCAM-1) [37], which help facilitate leukocyte
movement into the peritoneal cavity [38]. TIMP-1-GPI did not
influence ICAM-1 expression on the surface of treated cells, but
did moderately increase VCAM-1 expression.
In addition to mesothelial denudation, a hypercoagulatory state
in the peritoneal cavity can also contribute to the thickening of the
peritoneal membrane in chronic inflammation [39] and during
adhesion formation following surgical procedures [40–41]. Meso-
thelial cells produce components of a plasma independent
fibrinolytic system: t-PA and uPA are fibrinolytic agents while
PAI-1 inhibits their fibrinolytic potential. Disturbances in the
balance of the fibrinolytic agents or their inhibitor have been
demonstrated following surgical trauma episodes or PD associated
peritonitis, or after stimulation of cultured mesothelial cells with
proinflammatory agents [19,20,42].
Treatment with TIMP-1-GPI led to a dose dependent decrease
in PAI-1 and an increase in t-PA secretion, as well as a decrease in
uPA production. t-PA plays a pivotal role in the fibrinolytic system
by converting the proenzyme plasminogen in the active enzyme
plasmin, a potent broad-spectrum protease that cleaves fibrin.
Moreover plasmin is able to degrade several components of
extracellular matrices by activating latent procollagenases and
metalloproteases [43,44]. Mesothelial uPA production is of minor
importance for the intraperitoneal fibrinolytic system, as t-PA
activity exceeds it by far [13]. Treatment with TIMP-1-GPI
shifted this balance to fibrinolysis that occurs in conjunction with
facilitated wound repair.
Human mesothelial cells undergo apoptosis during peritonitis
which may be related to the resolution of peritoneal
inflammation [45]. Elevated levels of TNF-a are found in the
peritoneal fluid from CAPD patients undergoing episodes of
peritonitis [21]. TNF-a directs mesothelial cells to undergo
apoptosis via the Fas/Fas ligand pathway [22]. Mesothelial cells
can be a source of intraperitoneal TNF-a, especially in response
to noxious stimulants [46]. Treatment with TIMP-1-GPI lead to
reduced mesothelial TNF-a release. In addition, treatment also
moderately reduced the expression of FAS receptor expression
on the surface of TIMP-1-GPI-treated cells. TIMP-1-GPI-
treated cells showed approximately 20% less FAS receptor
expression (by FACS) than that seen in controls (data not
shown).
The role of MMP/TIMP biology in cellular proliferation and
migration is complicated and appears to depend upon the type
and activation state of the cells involved [6,7,8]. MMPs can
moderate autocrine and paracrine factors linked to these
processes. Many factors such as TGF-b1 and TNF-a are
synthesized as precursor proteins that require proteolytic
processing to gain functional activity [47,48]. TGF-b1 can
effectively block the migration and proliferation of mesothelial
cells [24,25]. MMP-2 and MMP-9 activate TGF-b through
proteolytic degradation of the latent TGF-b1 complex [47].
These MMPs are sequestered at the cell surface by TIMP-1-GPI
treatment. This is associated with a reduction in the processing of
TGF-b1 to its active form, and in parallel, a reduction in TNF-a
secretion and steady state mRNA.
Exogenously applied TIMP-1-GPI fusion protein is incorporat-
ed into mesothelial surface membranes leading to a direct focusing
the biologic actions of TIMP-1 onto the cell surface. This surface
engineering has robust effects on mesothelial biology. Treatment
reduced MMP release and leads to accelerated wound closure
through the activation of proliferation and migration of mesothe-
lial cells and moderated the fibrogenic environment. Treatment
with TIMP-1-GPI may show efficacy in the repair of damaged
mesothelium.
Supporting Information
Text S1 RT-PCR analyses.
(DOC)
Figure S1 TIMP-1-GPI treatment moderates the steady
state TNF-a, PAI-1 and t-PA gene expression. Primary
human mesothelial cells were left untreated, or were treated with
7 ng/ml TIMP-1-GPI, 14 ng/ml TIMP-1-GPI, 14 ng/ml of heat
treated TIMP-1-GPI or 14 ng/ml of rhTIMP-1. After 48 hrs
RNA was isolated and subjected to analysis using TaqMan RT-
Figure 8. TIMP-1-GPI impacts TGF-b1 expression and process-
ing. TGF-b1 can inhibit mesothelial cell migration and proliferation.
MMP-9 and MMP-2 can proteolytically activate latent TGF-b1. Cell
surface engineering with TIMP-1-GPI leads to a reduction in the
expression and processing of latent TGF-b1 to its active form.
doi:10.1371/journal.pone.0033963.g008
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PAI-1.
(EPS)
Video S1 Medium control.
(AVI)
Video S2 Vehicle control.
(AVI)
Video S3 Control rTIMP-1 14 ng/ml.
(AVI)
Video S4 TIMP-1-GPI 7 ng/ml.
(AVI)
Video S5 TIMP-1-GPI 14 ng/ml.
(AVI)
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